Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.
about
Tools to define the melanoma-associated immunopeptidome.Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth.Role of LFA-1 and ICAM-1 in Cancer.Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.Discovery and application of immune biomarkers for hematological malignancies.Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer.New Chimeric Antigen Receptor Design for Solid Tumors.The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.mTOR at the Transmitting and Receiving Ends in Tumor Immunity.T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.Transcriptional programming of tissue-resident memory CD8+ T cells.Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma.Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity.The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activityBCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell StemnessRenin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity
P2860
Q38650013-770D98E3-F94D-47D0-9DF2-AAD160A96DC9Q42378297-EF8840C3-06E5-45B3-8326-D5E62601076DQ46166018-0FAC36C9-D5C2-4591-ACB3-1BAA463EF0E3Q47106562-30AB7A52-359F-4BAE-B65B-E463F4D770BBQ47382765-980B3E4D-7F96-49B4-B19D-8BCDD6913D66Q47681393-3C617344-CD39-479D-8A45-862628288D34Q48251095-9B01B923-5E70-4A88-9A1D-056087B67966Q49711158-EC19ECF5-484B-479E-9876-E20508ADEF3EQ49843616-744BB453-9E00-4892-A022-489E4E0B91D4Q52319565-3ADC3F25-6B10-4B58-B961-55703493647EQ52593234-61D62EDD-301C-47DE-9F5F-35CD678FB636Q52721322-C1B9D15B-04B5-45B5-9672-894E677E2A02Q53697047-941BA9D3-3EC9-4B6B-B936-9DA80177C840Q54213332-47DF5388-837F-4C47-9AEB-12A2E12016EBQ54979633-B16471A5-CADA-421F-8228-5F719205E7E7Q55023271-738EE011-A70A-42BA-8080-B057E68BC74AQ57285558-D55C2D2E-4859-45A7-A0D3-39F6D6589CB4Q58797150-EE990B73-A93B-4773-BA72-EA9FAC3F4DACQ59125636-1DCC3917-D7B2-4BB9-ADAC-BDB5B804BCB6
P2860
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Obstacles Posed by the Tumor M ...... ase for Synergistic Therapies.
@en
Obstacles Posed by the Tumor M ...... ase for Synergistic Therapies.
@nl
type
label
Obstacles Posed by the Tumor M ...... ase for Synergistic Therapies.
@en
Obstacles Posed by the Tumor M ...... ase for Synergistic Therapies.
@nl
prefLabel
Obstacles Posed by the Tumor M ...... ase for Synergistic Therapies.
@en
Obstacles Posed by the Tumor M ...... ase for Synergistic Therapies.
@nl
P2860
P1433
P1476
Obstacles Posed by the Tumor M ...... Case for Synergistic Therapies
@en
P2093
Ingunn M Stromnes
Philip D Greenberg
P2860
P304
P356
10.1016/J.CCELL.2017.02.008
P577
2017-03-01T00:00:00Z